Press Releases

MYnd Analytics’ Canadian Forces Clinical Trial Featured by National Post

MISSION VIEJO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (OTCQB:MYAN), a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients, announced today that Canada’s National Post newspaper featured the company’s SMART-MD clinical trial with Canadian Forces as a revolutionary way to treat PTSD among veterans.

The Canadian army’s top psychiatrist, Col. Rakesh Jetly, explained his interest in MYnd Analytics’ PEER technology by saying “It is a Big Data idea combining a classic test — the EEG — with a modern concept. This is how Google works, it looks for trends.”

Col. Jetly brought PEER to Canada after learning about the positive impact on service members when the PEER Report was utilized to assist Walter Reed physicians in selecting medications that were personalized for their patients.

PEER technology uses algorithms and a database consisting of outcomes from more than 10,000 patients to generate an objective report which can help a physician select the right mental health medication for an individual as opposed to “treatment as usual” which involves a significant degree of trial and error.  Whether a sergeant or a general, the article notes, many veterans with PTSD never get relief because of the constant medication swapping. MYnd Analytics may offer them hope, by taking the guesswork out of prescribing.

“With ongoing replication trials and the deployment of our mobile app, we continue to see positive outcomes from our technology and are hopeful it will become a standard tool for clinicians to improve the quality of patient care,” said George Carpenter, CEO, MYnd Analytics.

Read the National Post article here.

About MYnd Analytics, Inc.

MYnd Analytics, Inc. ( provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications. 

To read more about the benefits of this patented technology for patients, physicians and payers, please visit

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Media Contact:
Lauren Jenkins
(202) 596-5669

Primary Logo

Source: MYnd Analytics, Inc.